Literature DB >> 15108026

Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG.

Martijn P Gosselink1, W Rudolph Schouten, Leo M C van Lieshout, Willem C J Hop, Jon D Laman, Johanneke G H Ruseler-van Embden.   

Abstract

PURPOSE: Proctocolectomy with ileal pouch-anal anastomosis is the operation of choice for patients with refractory or fulminant ulcerative colitis. The most common long-term complication in these patients is pouchitis. This study was designed to investigate the efficacy of probiotic Lactobacillus rhamnosus GG in long-term delaying the first onset of pouchitis.
METHODS: Between 1989 and 2001, a consecutive series of 127 patients presenting with ulcerative colitis underwent an ileal pouch-anal anastomosis at the Erasmus Medical Center in Rotterdam. Histopathologic investigation of the resected specimens revealed unsuspected Crohn's disease in five patients. Postoperative complications resulted in pouch excision in five patients. The remaining 117 patients were included in this study. All episodes of pouchitis occurring in this group were analyzed. Pouchitis was diagnosed on the basis of clinical symptoms and endoscopic and histologic features. The 39 patients, who underwent an ileal pouch-anal anastomosis between 1996 and 2001, started immediately after the operation with the daily intake of L. rhamnosus GG in a fermented product. The 78 patients, in whom an ileal pouch-anal anastomosis was performed between 1989 and 1996, received no L. rhamnosus GG.
RESULTS: Except for the duration of follow-up, the patient characteristics, indications for proctocolectomy, number of postoperative complications, and functional outcome were similar in both groups. First episodes of pouchitis were observed less frequently in patients with a daily intake of L. rhamnosus GG (cumulative risk at 3 years: 7 vs. 29 percent; P = 0.011).
CONCLUSIONS: Daily intake of fermented products containing L. rhamnosus GG provides significant clinical benefit, without side effects. Based on the results of this study, we recommend a daily intake of Lactobacillus rhamnosus GG (dose 1-2 x 10(10) bacteria) to delay the first onset of pouchitis.

Entities:  

Mesh:

Year:  2004        PMID: 15108026     DOI: 10.1007/s10350-004-0525-z

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  38 in total

Review 1.  Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.

Authors:  Bo Shen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-04-17       Impact factor: 46.802

Review 2.  A gastroenterologist's guide to probiotics.

Authors:  Matthew A Ciorba
Journal:  Clin Gastroenterol Hepatol       Date:  2012-04-10       Impact factor: 11.382

Review 3.  Probiotics in the management of inflammatory bowel disease.

Authors:  Robert M Penner; Richard N Fedorak
Journal:  MedGenMed       Date:  2005-07-18

Review 4.  Probiotics in pediatric inflammatory bowel diseases.

Authors:  Ajay S Gulati; Marla C Dubinsky
Journal:  Curr Gastroenterol Rep       Date:  2009-06

Review 5.  Probiotics for the treatment of inflammatory bowel disease.

Authors:  Ganesh R Veerappan; John Betteridge; Patrick E Young
Journal:  Curr Gastroenterol Rep       Date:  2012-08

6.  The emerging therapeutic role of probiotics in inflammatory bowel disease.

Authors:  Matthew Chandler; Eric Wollins; Anastasia Toles; Marie Borum; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-09

Review 7.  The Failed J Pouch.

Authors:  Emmanouil P Pappou; Ravi P Kiran
Journal:  Clin Colon Rectal Surg       Date:  2016-06

Review 8.  Diet therapy for inflammatory bowel diseases: The established and the new.

Authors:  Franziska Durchschein; Wolfgang Petritsch; Heinz F Hammer
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

9.  Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis.

Authors:  I J J Claes; Sarah Lebeer; C Shen; T L A Verhoeven; E Dilissen; G De Hertogh; D M A Bullens; J L Ceuppens; G Van Assche; S Vermeire; P Rutgeerts; J Vanderleyden; S C J De Keersmaecker
Journal:  Clin Exp Immunol       Date:  2010-08-20       Impact factor: 4.330

Review 10.  Probiotics in the management of colonic disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2007-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.